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  HIP
A feasibility study to assess the design 
of a multicentre randomized controlled 
trial of the clinical and cost- effectiveness 
of a caregiving intervention for people 
following hip fracture surgery
Aims
This study aims to assess the feasibility of conducting a pragmatic, multicentre randomized 
controlled trial (RCT) to test the clinical and cost- effectiveness of an informal caregiver train-
ing programme to support the recovery of people following hip fracture surgery.
Methods
This will be a mixed- methods feasibility RCT, recruiting 60 patients following hip fracture 
surgery and their informal caregivers. Patients will be randomized to usual NHS care, versus 
usual NHS care plus a caregiver- patient dyad training programme (HIP HELPER). This pro-
gramme will comprise of three, one- hour, one- to- one training sessions for the patient and 
caregiver, delivered by a nurse, physiotherapist, or occupational therapist. Training will be 
delivered in the hospital setting pre- patient discharge. It will include practical skills for reha-
bilitation such as: transfers and walking; recovery goal setting and expectations; pacing and 
stress management techniques; and introduction to the HIP HELPER Caregiver Workbook, 
which provides information on recovery, exercises, worksheets, and goal- setting plans to fa-
cilitate a ‘good’ recovery. After discharge, patients and caregivers will be supported in deliv-
ering rehabilitation through three telephone coaching sessions. Data, collected at baseline 
and four months post- randomization, will include: screening logs, intervention logs, fidelity 
checklists, quality assurance monitoring visit data, and clinical outcomes assessing quality 
of life, physical, emotional, adverse events, and resource use outcomes. The acceptability of 
the study intervention and RCT design will be explored through qualitative methods with 20 
participants (patients and informal caregivers) and 12 health professionals.
Discussion
A multicentre recruitment approach will provide greater external validity across population 
characteristics in England. The mixed- methods approach will permit in- depth examination 
of the intervention and trial design parameters. The findings will inform whether and how a 
definitive trial may be undertaken to test the effectiveness of this caregiver intervention for 
patients after hip fracture surgery.
Cite this article: Bone Jt Open 2021;2-11:909–920.
Keywords: Trauma, Hip fracture, Rehabilitation, Recovery, Caregiver, RCT
Introduction
Hip fracture is a prevalent and serious injury 
for older people.1 Approximately 80,000 
people aged 60  years and over experience 
a fragility hip fracture in the UK each year.2 
This has a combined health and social cost 
of £2  billion.3 Approximately 40% of these 
patients have cognitive impairment.1,4
People have frequently experienced 
poor recovery following hip fracture.5 The 
majority never return to their pre- injury level 
of function and independence,3,6 quality 
of life is reduced, and mortality is high.6,7 
Patients experience continued falls and re- in-
jury, which ultimately leads to reduced inde-
pendence and confidence in self- caring skills 
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to live at home. After sustaining a hip fracture, approx-
imately 20% of patients who previously lived at home 
move into institutional care.8 For those who do return 
home, informal caregivers frequently experience physical 
and mental stress when trying to support their friend’s/
family member’s recovery.5 A high caregiver burden has 
previously been reported by 20% of hip fracture care-
givers at six months post- surgery.9
Family members and friends in the role of informal 
caregivers are expected to support the transition from 
hospital to the community, facilitating the patient’s 
ongoing recovery.10 Tasks which informal caregivers may 
assist with range from personal activities of daily living 
(ADLs) such as toileting, washing, dressing, and eating, 
to more complex tasks such as managing money, shop-
ping and household chores.11
Qualitative evidence suggests that although informal 
caregivers want to support their friend/family member, 
they frequently feel under- skilled and have low confi-
dence to do so.12 A lack of information sharing, disorga-
nized discharge planning, and unclear individual roles 
and responsibilities are possible challenges for hip frac-
ture patients and their caregivers after returning home.13 
Teaching caregiver skills to better support patients 
following hip fracture may improve quality of life and 
independence, and reduce the burden of impairment for 
patients and caregivers.12,14
This study will investigate the feasibility of an inter-
vention designed to help improve health and wellbeing 
outcomes for patients and caregivers following hip frac-
ture. It will answer key research design uncertainties 
before further, definitive investigation is considered.
Methods
Aims and objectives. To assess the feasibility of conduct-
ing a pragmatic, multicentre randomized controlled trial 
(RCT) to test the clinical and cost- effectiveness of an in-
formal caregiver training programme to support the re-
covery of people following hip fracture surgery. The main 
objectives of this study are listed in Table I.
Trial design. A mixed- methods feasibility study compris-
ing a parallel, multicentre, pragmatic RCT and embedded 
qualitative study. The study flowchart is presented as 
Figure 1.
Study setting. Orthopaedic services providing hip frac-
ture surgery in five NHS hospital trusts in England: James 
Paget University Hospitals NHS Foundation Trust, City 
Hospitals Sunderland NHS Foundation Trust, Northumbria 
Healthcare NHS Foundation Trust, University Hospital 
Southampton NHS Foundation Trust, and Barts Health 
NHS Trust. They will provide geographical and social di-
versity, which is important given the cultural differences 
which exist in caring for friends and family members after 
illness or injury.15,16
Eligibility criteria. A minimum of 60 patient and 60 car-
egiver participants will be recruited.
 
Patient inclusion criteria:
1. Men and women aged 60 years and above who have 
undergone hip fracture surgery.
2. Has a nominated individual who will act as an informal 
caregiver and provides consent to participate in the 
study.
3. Community- dwelling prior to admission, alone or 
with a friend, relative, or caregiver.
4. Informed consent from the patient, or agreement 
from a consultee where the patient does not have ca-
pacity.
Caregiver inclusion criteria:
1. Is a caregiver for an eligible patient participant.
2. Willing and able to provide consent to participate.
3. If caregivers are unable to attend a hospital appoint-
ment for the face- to- face HIP HELPER intervention due 
to COVID- 19 (or equivalent) social measures, care-
givers must have access to a computer or tablet and 
internet services to receive a video consultation call.
An informal caregiver is defined as someone who has 
done or is expected to informally provide care, assistance, 
support, or supervision in ADLs for at least three hours 
Table I. HIP HELPER feasibility study objectives.
1. Feasibility of recruiting eligible people (patients (with/without cognitive impairment) and their caregivers) following hip fracture.
2. Acceptability to healthcare professionals of delivering a caregiver intervention to caregivers of patients with/without cognitive impairment.
3. Acceptability to caregivers of receiving a caregiver intervention for patients with/without cognitive impairment.
4. Fidelity of healthcare professionals to deliver the intervention in an NHS setting.
5. Fidelity of caregivers to deliver the intervention to patients at home.
6. Acceptability of randomization to caregiver intervention or standard NHS care for patients, caregivers, and healthcare professionals.
7. Risk of intervention contamination when experimental and control interventions are delivered in the same hospital ward.
8. Completeness of outcome measures (clinical and cost- effectiveness data collection tools) for people with/without cognitive impairment, and their 
caregivers.
9. To understand the patient and healthcare professional’s experiences of participating in the trial.
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per week, over two or more sessions per week, but is not 
contracted to do this on a paid basis. This may include 
activities ranging from personal ADLs such as toileting, 
washing, dressing, and eating, to more complex tasks 




1. Acute, unstable, or terminal illness which would make 
participation in the rehabilitation strategies contrain-
dicated and/or impractical.
2. Expected by the clinical team to be discharged to a 
care home (residential or nursing) after their hospital 
admission or rehabilitation unit outside the recruiting 
site.
3. Participation in other treatment trials, where this has 
not been agreed in advance with both trial teams.
Recruitment
Site teams will aim to approach and consent eligible 
patients and caregivers within 72 hours postoperatively. 
Both will be provided with Participant Information Sheets 
(PIS). For eligible patients, the initial approach may be 
pre- or postoperatively on the hospital ward. For care 
providers, the approach may be on the hospital ward or 
by telephone, to provide both groups time to consider 
trial participation. Timing of approach and consent will 
be recorded as a feasibility outcome. Written informed 
consent (Supplementary File 1) will be obtained prior to 
any trial- specific procedures being performed.
Best efforts will be made to involve patients who may 
lack capacity in the decision to enrol. Potential patient 
Fig. 1
Study flowchart.
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participants will be assessed by the site research team 
to determine whether they have the mental capacity to 
give informed consent. When a patient is deemed to 
have capacity by a healthcare professional, informed 
consent will be sought. When a patient is deemed to 
lack capacity by a healthcare professional (in accordance 
with the Mental Capacity Act),17 advice will be sort from 
a personal consultee on whether the patient should take 
part, and what their past wishes and feelings would have 
been about taking part. This will be supported with a 
Consultee PIS. If in agreement, they will be asked to sign 
a Consultee Declaration Form (Supplementary File 2). In 
agreement with the consultee, the researcher will discuss 
the trial with the patient participant to gain assent to 
participate wherever possible. Where the consultee is 
also the nominated caregiver, they will also be provided 
with the Caregiver PIS and asked to complete the Consent 
Form (Supplementary File 1) to consent for that role in 
the research.
Sites will record (during the trial’s recruitment period), 
the number of people screened and reasons why poten-
tial participants were ineligible and/or not approached. 
Eligible participants who are approached but who decline 
to participate will be anonymously recorded as part of a 
screening log, providing information on sex and, when 
provided, the reason(s) for declining participation. Modi-
fications to study processes as a result of COVID- 19 social 
restrictions (when enacted) are outlined in Supplemen-
tary File 3.
Randomization and blinding. Consented patient partici-
pants will be registered for randomization by a member 
of the research team. Allocation will be concealed prior 
to randomization to prevent allocation bias. Electronic 
randomization will be performed through the Norwich 
Clinical Trials Unit (NCTU). Randomization will be at 
the patient- caregiver dyad level (1:1 experimental and 
control groups) by minimization for 1) hospital and 2) 
presence of patient cognitive impairment (Abbreviated 
Mental Test Score (AMTS))18 < or ≥ eight points.
The patient will be allocated a participant identifi-
cation number at time of consent. Once the baseline 
data are collected, and pre- designated questions in the 
Case Report Form (CRF) entered, the research team will 
randomize that participant dyad. The treatment allo-
cation will be revealed and linked to that participant 
number.
Due to the participatory nature of the intervention, 
patient and caregiver participants and the research team 
will be unblinded to treatment allocation.
Intervention
Control intervention: NHS usual care. This will be received 
by both control and intervention groups. Usual care will 
be NHS treatment as usual. This consists of pre- discharge 
care including nursing, physiotherapy, occupational 
therapy, and social service assessment (where appropri-
ate). Unlike the experimental intervention, there is no 
routine ‘training’ element for caregivers. Post- discharge 
physiotherapy and occupational therapy is not usually 
provided for this population.19,20 Following standard NHS 
care, patients and their caregivers will not receive the HIP 
HELPER programme, with no additional training as an in-
patient or out- patient. Control intervention logs will be 
used to record usual care to monitor local service provi-
sion and any changes during the study.
Experimental intervention: HIP HELPER training pro-
gramme. HIP HELPER is a patient- caregiver dyad train-
ing programme. The theoretical principle behind the 
programme is a social learning theory.21 The theoret-
ical background of the intervention is presented in 
Supplementary File 4.
The first session will start within six days postoper-
atively. The following two sessions will be delivered 
after this time, but prior to inpatient hospital discharge. 
Session timings will be determined by the HIP HELPER 
clinical team based on clinical presentation, expected 
duration of hospital stay, and caregiver availability. These 
sessions will be delivered in the hospital, provided to both 
patient and caregiver as a dyad by either a nurse, physio-
therapist, or occupational therapist, depending on ward 
staffing. All staff delivering the HIP HELPER programme 
completed a one- day training programme delivered by 
the HIP HELPER programme developers.
Each HIP HELPER programme session will take a 
maximum of 60 minutes. These sessions will include:
 
Session 1
 Explanation on normal recovery pathways and expec-
tations on functional recovery.
  Practical skills to teach caregivers how to aid transfer 
from bed- chair and how to safely walk with the 
patient using walking aids.
  Education on patient- caregiver shared goal- setting in 
the early postoperative period.
  Teach principles of pacing and behaviour modifica-
tion in the early post- discharge period.
 Introduction and explanation of the HIP HELPER 
Workbook, highlighting material on normal recovery, 
goal setting, action planning, problem- solving.
Session 2
 Refresher and reinforcement of practical skills to teach 
caregivers how to aid bed- chair (and the like) trans-
fers, mobility and washing, dressing, and personal 
activities of daily living, dependent on patient- 
caregiver needs.
  Revision on constructed patient- caregiver shared 
goals.
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  Develop knowledge on stress management, pacing, 
and behaviour modification linked to goals in the first 
two postoperative weeks.
 Revision throughout the session on how these skills 
link to normal recovery pathways and expectations 
on functional recovery.
Session 3
 Refresher and revision/reinforcement on practical 
skills to teach caregivers how to aid transfer from bed- 
chair and how to safely walk with the patient using 
walking aids.
  Discussion on stress management and caregiver 
pacing, and how these may link to defined goals and 
behaviour modification.
  Working through case- study scenarios of the recovery 
pathway in the initial six weeks post- discharge, to 
reinforce knowledge and critique competencies on 
HIP HELPER skills.
  Revision and refresher on the HIP HELPER Workbook.
 Confirmation of dates for HIP HELPER Telephone 
Booster calls.
HIP HELPER telephone sessions. Following hospital dis-
charge, a HIP HELPER healthcare professional will tele-
phone each caregiver and patient (dependent on cog-
nitive impairment) as a dyad during Week 1, 3, and 6 
post- hospital discharge. Each call is expected to take ap-
proximately 20 minutes. Both caregiver and patient par-
ticipant should be in the same room during these tele-
phone calls. Topics covered in each call will include:
 Recovery progress and current status based on 
patient- caregiver shared goals.
  Discussion on HIP HELPER Workbook use and progress 
including home hazard falls assessment.
  Review behaviour and outcome goals and problem- 
solve together.
  Advice on any difficulties and signposting to other 
healthcare professionals when appropriate, based on 
NICE guidelines.22
 Support to create collaborative goals for continued 
recovery.
Patients with cognitive impairment will be involved 
throughout the inpatient sessions and with workbook 
and telephone activities. The degree of cognitive impair-
ment will determine how actively engaged the patient 
will be with the training element, as determined by the 
HIP HELPER healthcare professional.
Co-interventions. Patient- caregiver dyads in either group 
will not be asked to desist from receiving other forms of 
treatment during the trial such as continuing rehabilita-
tion, general practitioner (GP) consultations, medication 
changes, or alternative treatments if required. Use of 
these treatments will be recorded through a health re-
source use questionnaire.
Assessments
Baseline assessment. Patient and caregiver baseline as-
sessments will be undertaken after consent has been 
obtained, prior to randomization. Paper- based question-
naire will include patient data on hospital admission, 
age, sex, ethnicity, height, weight, patient cognitive im-
pairment assessed using the AMTS,18 past medical histo-
ry, American Society of Anesthesiologists (ASA) grade,23 
side of hip fracture, operative procedure, and hip fracture 
classification.
Caregiver demographic data collected will include: 
relationship of caregiver to patient, caregiver age, sex, 
ethnicity, past medical history, AMTS, whether they live 
with the patient (distance lived away), employment 
status, and experience of being a caregiver (for this 
patient and/or for another person).
Outcome measures. The data collection schedule is pre-
sented in Table II.
Outcomes. To answer our feasibility objectives we will 
assess recruitment feasibility by screening log data on: 
number of potential participants and their caregivers 
screened, assessed for eligibility, including reasons for 
exclusion/non- participation, and consented to be rand-
omized, timing and location of approach, and consent.
1. Intervention acceptability – by qualitative interviews 
with participants; acceptability questionnaire, study 
attrition at the intervention phase.
2. Intervention fidelity (healthcare professionals) – by 
intervention log data on postoperative timing, HIP 
HELPER session duration, frequency, location (ortho-
paedic/orthogeriatric ward, rehabilitation ward, or 
other); Quality Assurance (QA) to monitor HIP HELPER 
programme delivery.
3. Intervention fidelity (caregivers) – by caregiver HIP 
HELPER programme intervention logs; qualitative 
interviews.
4. Randomization acceptability – by screening logs, 
eligibility assessment logs, and consent forms; partic-
ipant attrition; qualitative investigation.
5. Risk of contamination – by HIP HELPER programme 
log data including QA monitoring visit checklists; 
delegation logs; and qualitative interviews with 
healthcare professionals.
6. Completeness of outcome measures – by completion 
rates (baseline and four months post- randomization).
At four months post- randomization, patient participants 
and caregivers will be sent a postal follow- up question-
naire. If participants have not responded within 14 days of 
posting, up to two telephone reminders will be made by 
the trial team. If required, a second postage of the ques-
tionnaires will be provided if requested by the participant 
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Table II. Participant timeline illustrating schedule of enrolment, interventions, and assessments.




discharge Home Follow- up
Timepoint   Up to 3 days 
postoperatively
+ 24 hrs after 
consent visit





Enrolment                 
Initial approach               
Informed consent               
Randomization                 
Interventions                 
Experimental (usual care 
+ HIP HELPER)
                
Control (usual care)                 
Assessments                 
Screening logs                 
Adverse event reporting                 
Date of hospital 
admission
                
Age                 
Sex               
Ethnicity                 
Height and weight                 
Past medical history                 
AMTS                 
Side hip fracture                 
Hip fracture classification                 
Patient residential status                 
Patient (non- CIm) EQ- 
5D- 5L
                
Patient (non- CIm) NEADL                 
Patient (non- CIm) GSE                 
Patient (non- CIm) CES- D                 
Patient (non- CIm) NRS 
Pain
                
Patient (Clm) EQ- 5D- 5L 
proxy
                
Patient (CIm) DADS- 6                 
Patient (CIm) NPI                 
Patient (CIm) Abbey Pain 
Scale
                
Relationship of caregiver 
to patient
                
Caregiver age                 
Caregiver sex                 
Caregiver AMTS                 
Caregiver past medical 
history
                
Caregiver caregiving 
experience
                
Caregiver residential 
status to patient
                
Caregiver employment 
status
                
Caregiver EQ- 5D- 5L                 
Caregiver CES- D                 
Caregiver SCQ- 16                 
Caregiver Resource 
Utilization in Dementia 
questionnaire
                
HCP intervention logs                 
ASA                 
Operative procedure                 
Patient length of hospital 
stay
                
Patient discharge 
destination
                
Continued
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during these follow- up telephone calls. In the event of a 
COVID- 19 (or equivalent) social measures limiting partic-
ipants’ abilities to return postal questionnaires, the trial 
team will initially telephone these participants (care-
givers and care recipient) to offer the ability for telephone 
or postal questionnaire completion. If these methods fail, 
the participant would be categorized as a non- responder 
for that timepoint only.
Outcome measures collected will include:
Patients without cognitive impairment
 EQ- 5D- 5L health resource use questionnaire24
  Nottingham Activities of Daily Living Scale (NEADL)25
  General Self- Efficacy questionnaire26
  Centre for Epidemiologic Studies Depression Scale 
(CES- D)27
  Numerical rating scale (NRS) for pain28
 Complications and adverse events including mortality 
(four- month follow- up only).
For all caregivers
 EQ- 5D- 5L24
  CES- D27
  Short Sense of Competence Questionnaire for 
caregiver burden (SCQ- 16)29
  Resource Utilization in Dementia questionnaire11
  Complications and adverse events including mortality 
(four- month follow- up only).
 Patient and caregiver residential status (single 
question).
Plus for caregivers of patients with cognitive impairment
 EQ- 5D- 5L proxy24
  Disability Assessment for Dementia Scale- 6 (DADS- 6) 
functional score30
  Neuropsychiatry Inventory (NPI)31
 Abbey Pain Scale32
These measures were selected due to their favour-
able psychometric properties and relevance as judged 
by Patient and Public Involvement (PPI) and clinician 
feedback. They satisfy Haywood et al’s33 core outcome 
set for hip fracture trials, listed in the COMET Initiative 
database.34
Data analysis
Sample size. As this feasibility trial does not aim to as-
sess treatment effects, we have not undertaken a formal 
power sample size calculation. However, careful consid-
eration has been made as to the number of participants 
required to answer the feasibility objectives.
In total, 60 participant dyads (60  patients/60 care-
givers) will be recruited. A maximum of 30 patients with 
cognitive impairment (AMTS ≤ 8 points) will be recruited, 
with a maximum of 15 patients per group. This sample 
size (and cognitive impairment subgroup) will be suffi-
cient to answer our feasibility objectives and assess the a 
priori progression criteria (Table I).35
Statistical analysis. The analysis of clinical outcome meas-
ures will be descriptive, reported as mean and standard 
deviations (SDs), or median and interquartile ranges if 
not normally distributed, for continuous outcomes and 
number and percentages for binary and categorical var-
iables. Consent rates, recruitment rates, attrition, miss-
ing data rates, and intervention fidelity will be reported 
as proportions with 95% and 85% confidence intervals 
(CIs). The mean difference, SD, and effect size will be es-
timated to determine direction and magnitude of effect, 
and to inform a power calculation for a definitive trial. No 
formal statistical testing will be undertaken.
Qualitative substudy
The objective of the qualitative study is to determine 
the patient and healthcare professional’s experiences of 
participating in this trial. The target population includes 
patient- caregiver dyads and physiotherapists, occupa-
tional therapists, and nursing staff who deliver the HIP 
HELPER intervention. A maximum of 30% of the dyads (n 
= 6 out of 20 dyads) in this qualitative study will include 
patients with cognitive impairment.
Patient-caregiver dyad interviews. Participant- dyads who 
have agreed to be contacted for the interview will be 
purposively sampled to ensure diverse representation. 




discharge Home Follow- up
Patient complications/
adverse events
                
Caregiver intervention 
home logs (intervention 
group only)
                
Caregiver acceptability 
questionnaire
                
Patient- caregiver semi- 
structured interviews
                
HCP semi- structured 
interviews
                
AMTS, Abbreviated Mental Test Score; ASA, American Society of Anesthesiologists; CES- D, Center for Epidemiological Studies Depression scale; CIm, cognitive impairment; DADS- 6, Disability 
Assessment for Dementia Scale- 6; EQ- 5D- 5L, EuroQol five- dimension five- level questionnaire; GSE, General Self- Efficacy questionnaire; HCP, healthcare professional; NEADL, Nottingham Activities 
of Daily Living Scale; non- CIm, non- cognitive impairment; NPI, neuropsychiatry inventory; NRS, numerical rating scale; SCQ- 16, Short Sense of Competence Questionnaire for caregiver burden.
Table II. Continued
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Targeted demographics will include age, ethnicity, pre- 
fracture disability (measured using the baseline NEADL25 
or DADS- 630), and cognitive impairment (AMTS).18 
Interviews will be conducted virtually using Microsoft 
Teams (Microsoft, USA) or telephone if this is not available.
Up to 20 face- to- face interviews will be conducted, 
involving 12 participant- dyads from the HIP HELPER 
group and eight from the standard care group across the 
four sites. Based on our previous research,36 this sample 
size should ensure a range of different viewpoints to 
answer our feasibility study questions. Thirty percent 
of the dyads (n = 6) will include patients with cognitive 
impairment.
We will invite the dyad to be interviewed together. If 
this does not suit the dyad for any reason, we will invite 
each member to be interviewed separately. Interviews 
will be conducted up to six weeks post- discharge from 
hospital. This allows exploration of the patient and care-
giver’s study experience at home in a reasonable recall 
period. Interviews will be semi- structured, following an 
open- ended question schedule, with a maximum dura-
tion of 60 minutes. Questions for the intervention group 
will capture acceptability of the intervention and the 
outcome measures, and any contextual influences and 
adaptions that have affected fidelity. The caregiving dyad 
interview topic guide is presented as Table III.
Healthcare professional interviews. The healthcare pro-
fessionals delivering the HIP HELPER intervention will be 
interviewed after delivering their first HIP HELPER pro-
gramme session(s). A minimum of one physiotherapist, 
one nurse, and one occupational therapist who delivered 
the intervention will be interviewed from each site (12 
participants in total). This will provide a range of con-
texts from different professional backgrounds. Interviews 
will be conducted virtually using Microsoft Teams or via 
telephone (15 to 30  minutes). They will follow a semi- 
structured, open- ended question schedule. The health-
care professional interview topic guide is presented as 
Table IV.
Data collection and analysis. All interviews will be audio- 
recorded, and transcribed. After transcription the audio 
data will be destroyed and data anonymized. Data will 
be analyzed thematically taking a two- stage approach to 
understand the important contextual factors that have 
influenced the implementation of HIP HELPER. We aim 
to initially analyze all data deductively guided by the 
MRC guidance for complex interventions and process 
evaluations,37,38 to assess the quality of implementation, 
Table III. Topic guide for the caregiving dyad interviews.
The interview will be structured on the following areas of 
interest Sample questions
Introduction Overall, could you share your experiences of being involved with our research?
Determining participant views of their intervention First of all, can you talk me through what study treatment you received? (Prompt – 
clarify what was HIP HELPER and what was usual care/non- study intervention)
The approach and consent process and willingness to be randomized to 
either group
Can you talk me through how you got into the study? You were allocated to X 
group. What did that feel like? Could we have dealt with that differently?
The acceptability of the inpatient care (both groups) Would you be happy to talk me through your treatment while you were in the 
hospital?
As X’s carer, what was your impression of the care. For both of you, what was 
helpful and less helpful to your care?
Inpatient HIP HELPER programme and telephone booster calls 
(experimental group)
How far did you find the HIP HELPER programme helpful – for both of you. Can you 
give specific examples? What didn’t work as well?
Did you get the telephone calls? Can you remember what you talked about? Can 
you give specific examples of what was helpful, and l helpful? Was there any advice 
that confused you or you weren't clear about?
What the strengths of the experimental intervention What were the most helpful/good- bits of your HIP HELPER intervention? What was 
good about it. What didn’t you like about it?
What the weaknesses of the experimental intervention What were the less helpful/worse bits of the HIP HELPER intervention?
What modifications they may recommend to interventions received 
(standard care and experimental groups)
What could we improve? (Prompt: What do you think is lacking in the hospital? In 
the transition from hospital to home? In the home?)
How do you think we could better support you and your carer to recover after hip 
surgery? What do you think is lacking in the hospital? In the transition from hospital 
to home? In the home?
The risk of intervention contamination between the groups Did you talk to any other patients or caregivers while in hospital about the 
intervention? Was there any discussion between those who received it and did not 
receive it?
The ease and convenience of the data collection processes (baseline and 
4 mths) (all participants)
As you were part of a trial, we had to collect a lot of measurements. Can you talk 
me through what these were? How easy were they? How convenient were they? 
Overall, do you have any points to make about the testing?
Applicability of the methods and measures used How did you manage with the questionnaires we gave you at the start of the study 
and at the end in the post? Were they easy to complete or do you remember them 
being a problem?
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clarify the hypothesized causal mechanisms identified in 
our logic model (for example, goal setting in the inpa-
tient training and the support provided by the telephone 
coaching), and identify contextual factors associated with 
variation in outcomes. Data will then be analyzed more 
inductively and more broadly. This will include critiquing 
the conceptual approach of HIP HELPER, understanding 
any unintended consequences, and reflections on the in-
tervention from the healthcare professional, patient, and 
caregiver perspective.
Progression criteria. A ‘traffic light’ system will be used 
as a guide for progression to a definitive trial.39 The pro-
gression criteria are listed in Table V. If any of the criteria 
are not met, these will be discussed by the Trial Oversight 
Committee (TOC) to decide if a definitive trial is feasible.
Data management. All data will be processed according 
to the Data Protection Act 2018,40 and all documents will 
be stored safely in confidential conditions. Trial- specific 
documents, except for the signed consent form and 
follow- up contact details, will refer to the participant 
with a unique study participant number, not by name. 
Participant identifiable data will be stored separately from 
trial data. All trial data will be stored securely in offices 
or online in secure trial databases, only accessible by the 
central trial team in Norwich and authorized personnel.
Compliance, adherence, and quality assessment. The trial 
will be monitored and audited in accordance with the cur-
rent approved protocol, good clinical practice,41 relevant 
regulations, and standard operating procedures (SOPs). 
A rigorous quality control programme will be adopted to 
ensure intervention fidelity. We will collect data on what 
interventions (control and experimental) are delivered. 
This is with respect to intervention parameters including 
content, mode of delivery, personale delivered, frequen-
cy, timing of delivery, and variation/deviations from pro-
tocol. These will be collected through intervention logs 
completed by the healthcare professional delivering the 
intervention, and through relevant CRF questions.
Quality assurance checks through site visits will be 
conducted at Months 1, 3, and 6 from first randomization 
(approximately three weeks for each). These will be used 
to observe activities including (but not limited to) the 
Table IV. Topic guide for the healthcare professional interviews.
The interview will be structured on the 
following areas of interest Sample questions
Introduction Overall, could you share your experiences of being involved with our research?
The randomized to either group How did you feel about 50% of the patients not receiving the HIP HELPER intervention but getting 
normal care? Did this ‘sit easy’ with you?
The acceptability of the inpatient care How did the delivery of the HIP HELPER inpatient sessions go? How did you work out who would 
do what? Did shift working play a part inf deciding this? Was there a decision on professional 
background? Did you feel comfortable teaching all the content? Were any modifications made? How 
did the patients and caregivers get on with it in your opinion?
HIP HELPER telephone calls How did you feel about doing the telephone calls? Were they helpful for caregivers and patients? Was 
it feasible to deliver one call to both members of the dyad? How did you get on with patients who 
had cognitive impairment? Did you make any modifications to the content of the call?
Training on intervention Did you feel adequately prepared to deliver the inpatient and telephone HIP HELPER interventions? 
Would you recommend any changes to this? Did you need any additional ‘top up’ or ‘refresher’ 
training sessions?
The risk of intervention contamination between the 
groups
Do you think you used the HIP HELPER intervention on control or non- trial patients? Did other 
professionals not in the trial use the intervention? If either occurred, do you think anything could 
have been done to avoid this?
The ease and convenience of the data collection 
processes
As you were part of a trial, we had to collect a lot of measurements. How easy were the intervention 
data collection logs? How convenient were they? What changes would you recommend if any were 
needed?
Table V. Progression criteria.
Green (Go) Amber (Amend) Red (Stop)
Recruitment > 40% of patients screened across the 4 sites in 
12 months would be eligible
30% to 40% would be eligible < 30% would be eligible
Randomization 
acceptability
> 40% of eligible patients consent to be 
randomized
20% to 40% would be randomized < 20% would be randomized
Intervention fidelity 
(healthcare professionals)
> 70% of participants compliant with their 
allocated intervention (3 face- to- face sessions 
and booster phone call) as randomized
50% to 70% received intervention as 
randomized




> 90% (or patients with and without dementia) 
of participants adopted HIP HELPER intervention 
post- discharge
60% to 90% adopted HIP HELPER 
post- discharge
< 60% adopted HIP HELPER post- 
discharge
Contamination < 5% of participants in either group received 
majority of their allocated treatment crossover
5% to 10% of participants crossover > 10% of participants crossover
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experimental intervention sessions. If there are concerns 
in relation to any aspect of the site visit, repeat visits with 
training may be undertaken to improve a site’s protocol 
compliance.
Trial status. The trial is funded for 22 months and com-
menced in September 2020. Recruitment is expected to 
be complete by 31 October 2021 with the final follow- 
up visit for the final participant completed by 31 March 
2022. The trial will be completed by 31 June 2022.
Patient and public involvement. Patient involvement 
began during protocol development and continues 
throughout the trial. A patient- member will attend TOC 
meetings. The same patient- member is a co- investigator, 
providing insights into the trial conduct, particularly on 
data collection processes, and will help interpret the find-
ings to inform on the implications of the research during 
the trial’s dissemination phase.
Ethics and dissemination. Ethical approval was gained 
from the North East - Newcastle & North Tyneside 
1 Research Ethics Committee (REC) (20/NE/0213); 
16 March 2021). The trial was prospectively regis-
tered (Current Controlled Trials: ISRCTN13270387), 
Protocol version 3.0. Any amendments will be ap-
proved by the REC and Health Research Authority before 
implementation.
Reporting of the trial will be consistent with the 
CONSORT 201042 Statement (patient- reported outcomes 
and non- pharmacological interventions) and Template 
for Intervention Description and Replication (TIDieR)43 
guidelines. A summary of the results and trial materials 
will be made available via the trial website on comple-
tion. We will work with our PPI representatives to prepare 
materials to disseminate the findings to a lay audience. 
We will submit the final report to a peer- reviewed 
academic journal. Researchers outside the trial team may 
formally request a specific dataset using a data request 
form, which will be part of the Data Management Plan. 
All such requests will need to be approved by the Trial 
Management Group (TMG).
Trial management and oversight committees. Monthly 
TMG meetings will provide oversight for the day- to- day 
running of the trial.
A TOC, acting as a combined Trial Steering Committee 
and Data and Safety Monitoring Committee, is an inde-
pendent group responsible for oversight of the trial 
to safeguard the interests of trial participants. It will 
comprise independent clinicians, specialist physiother-
apists, statisticians, health service researchers, and PPI 
representatives with members of the trial team. They 
will also be convened to 1) detect any trends, such as 
increases in (un)expected events, and take appropriate 
action; 2) seek additional advice or information from 
investigators where required; and 3) evaluate the risk of 
the trial continuing, and take appropriate action where 
necessary.
The TOC will meet at least once every nine months for 
the duration of the study or more frequently as required.
Discussion
This paper presents the research protocol for the HIP 
HELPER study. It is hypothesized that supporting care-
givers on how to progress patient function, mobility, and 
overall health will address important patient health chal-
lenges and facilitate early recovery after hip fracture.12,44 
It may also reduce caregiver burden and depression asso-
ciated with caring for individuals. Following the lessons 
learnt in this feasibility study, it is hoped that this project 
will investigate an intervention designed to help improve 
health and wellbeing outcomes for patients following hip 
fracture in a future definitive trial.
Take home message
  - This study will investigate the feasibility of an intervention 
designed to help improve health and wellbeing outcomes for 
patients and caregivers following hip fracture.
  - The findings will inform the basis for a definitive trial to assess the 
effectiveness of a caregiver intervention for people following hip 
fracture.
Twitter
Follow T. Smith @tobyosmith
Follow S. Hanson @walkingresearch
Follow A. Welsh @alliecwelsh
Supplementary material
  Participant (patient and caregiver) consent form, 
consultee declaration form, modifications to the 
protocol as a result of COVID- 19 pandemic, and 
document outlining the theoretical underpinning of the 
HIP HELPER intervention.
References
 1. NHFD. Assessment benchmark summary 2018. https://www. nhfd. co. uk/ tables (date 
last accessed 6 February 2019).
 2. Mitchell P, Bateman K, Novartis. Dementia, Falls and Fractures. Integrated 
Approaches to Improve Quality and Reduce Costs. 2012. https://www. bristol. gov. 
uk/ documents/ 20182/ 759292/ Dementia% 2C+ falls+ and+ fractures/ bc9264b1- 74fa- 
46b0- b868- a2cf93de82f5 (date last accessed 29 September 2021).
 3. Dyer SM, Dyer SM, Crotty M, et al. Fragility fracture network (FFN) rehabilitation 
research special interest group. A critical review of the long- term disability outcomes 
following hip fracture. BMC Geriatr. 2016;16:158.
 4. Seitz DP, Adunuri N, Gill SS, Rochon PA. Prevalence of dementia and 
cognitive impairment among older adults with hip fractures. J Am Med Dir Assoc. 
2011;12(8):556–564. 
 5. Lawler K, Taylor NF, Shields N. Involving family members in physiotherapy for 
older people transitioning from hospital to the community: a qualitative analysis. 
Disabil Rehabil. 2015;37(22):2061–2069. 
 6. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and 
disability associated with hip fracture. Osteoporos Int. 2004;15(11):897–902. 
 7. Griffin XL, Parsons N, Achten J, Fernandez M, Costa ML. Recovery of health- 
related quality of life in a United Kingdom hip fracture population. The Warwick HIP 
Trauma Evaluation--a prospective cohort study. Bone Joint J. 2015;97- B(3):372–382. 
 8. Nurmi I, Narinen A, Lüthje P, Tanninen S. Cost analysis of hip fracture treatment 
among the elderly for the public health services: A 1- year prospective study in 106 
consecutive patients. Arch Orthop Trauma Surg. 2003;123(10):551–554. 
 9. Parry JA, Langford JR, Koval KJ. Caregivers of hip fracture patients: The forgotten 
victims? Injury. 2019;50(12):2259–2262. 
VOL. 2, NO. 11, NOVEMBER 2021
ASSESSING THE DESIGN OF A MULTICENTRE RCT OF THE CLINICAL AND COST- EFFECTIVENESS OF A HIP FRACTURE CAREGIVING INTERVENTION 919
 10. Ariza- Vega P, Ortiz- Piña M, Kristensen MT, Castellote- Caballero Y, Jiménez- 
Moleón JJ. High perceived caregiver burden for relatives of patients following hip 
fracture surgery. Disabil Rehabil. 2019;41(3):311–318. 
 11. Wimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the resource 
utilization and caregiver time in anti- dementia drug trials - a quantitative battery. 
In: Wimo A, Karlsson G, Jönsson B, Winblad B, editors. The Health Economics of 
Dementia. London, UK: Wiley’s. 1998.
 12. Saletti- Cuesta L, Tutton E, Langstaff D, Willett K. Understanding informal carers’ 
experiences of caring for older people with a hip fracture: a systematic review of 
qualitative studies. Disabil Rehabil. 2018;40(7):740–750. 
 13. Asif M, Cadel L, Kuluski K, Everall AC, Guilcher SJT. Patient and caregiver 
experiences on care transitions for adults with a hip fracture: A scoping review. 
Disabil Rehabil. 2020;42(24):3549–3558. 
 14. Giosa JL, Stolee P, Dupuis SL, Mock SE, Santi SM. An examination of 
family caregiver experiences during care transitions of older adults. Can J Aging. 
2014;33(2):137–153. 
 15. Dilworth- Anderson P, Williams IC, Gibson BE. Issues of race, ethnicity, 
and culture in caregiving research: a 20- year review (1980- 2000). Gerontologist. 
2002;42(2):237–272. 
 16. Fernández- Ballesteros R, Sánchez- Izquierdo M, Olmos R, et  al. Cultural 
stereotypes in care contexts. Clin Interv Aging. 2018;13:1613–1619. 
 17. No authors listed. Mental Capacity Act 2005. https://www. legislation. gov. uk/ 
ukpga/ 2005/ 9/ contents (date last accessed 24 September 2021).
 18. Hodkinson HM. Evaluation of a mental test score for assessment of mental 
impairment in the elderly. Age Ageing. 1972;1(4):233–238. 
 19. Chartered Society of Physiotherapy. 2018. Hip fracture rehabilitation in physiotherapy 
practice: From hospital to home. https://www. csp. org. uk/ publications/ hip- fracture- 
rehabilitation- physiotherapy- practice (date last accessed 6 February 2019).
 20. Royal College of Physicians. NHFD annual Report 2014. https://www. rcplondon. 
ac. uk/ projects/ outputs/ nhfd- annual- report- 2014 (date last accessed 29 September 
2021).
 21. Bandura A. Self- efficacy: toward a unifying theory of behavioral change. Psychol 
Rev. 1977;84(2):191–215. 
 22. NICE. Hip fracture management. https://www. nice. org. uk/ guidance/ cg124 (date last 
accessed 20 February 2017).
 23. Saklad M. Grading of patients for surgical procedures. Anesthesiology. 
1941;2(3):281–284. 
 24. Fernandez MA, Arnel L, Gould J, et al. Research priorities in fragility fractures 
of the lower limb and pelvis: a UK priority setting partnership with the James Lind 
Alliance. BMJ Open. 2018;8(10):e023301. 
 25. Gladman JR, Lincoln NB, Adams SA. Use of the extended ADL scale with stroke 
patients. Age Ageing. 1993;22(6):419–424. 
 26. Schwarzer R, Jerusalem M. Generalized Self- efficacy scale. In: Weinman J, 
Wright S, Johnston M, editors. Measures in Health Psychology: A User’s Portfolio. 
Causal and Control Beliefs. Windsor, UK: NFER- NELSON. 1995: 35–37.
 27. Radloff LS. The CES- D scale: A self- report depression scale for research in the 
general population. Appl Psycholog Measure. 1977;1:385–401.
 28. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance 
of changes in chronic pain intensity measured on an 11- point numerical pain rating 
scale. Pain. 2001;94(2):149–158. 
 29. Pendergrass A, Beische D, Becker C, Hautzinger M, Pfeiffer K. An abbreviated 
German version of the sense of competence questionnaire among informal 
caregivers of relatives who had a stroke: Development and validation. Eur J Ageing. 
2015;12(3):203–213. 
 30. de Rotrou J, Wu Y- H, Hugonot- Diener L, et  al. DAD- 6: A 6- Ltem version of 
the disability assessment for dementia scale which may differentiate Alzheimer’s 
disease and mild cognitive impairment from controls. Dement Geriatr Cogn Disord. 
2012;33(2–3):210–218. 
 31. Cummings JL, Mega M, Gray K, Rosenberg- Thompson S, Carusi DA, Gornbein 
J. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in 
dementia. Neurology. 1994;44(12):2308–2314. 
 32. Abbey J, Piller N, De Bellis A, et al. The Abbey pain scale: a 1- minute numerical 
indicator for people with end- stage dementia. Int J Palliat Nurs. 2004;10(1):6–13. 
 33. Haywood KL, Griffin XL, Achten J, Costa ML. Developing a core outcome set for 
hip fracture trials. Bone Joint J. 2014;96- B(8):1016–1023. 
 34. Comet. Core outcome measures in effectiveness trials. 2020. http://www. comet- 
initiative. org/ (date last accessed 11 March 2020).
 35. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. 
Sample size requirements to estimate key design parameters from external pilot 
randomised controlled trials: a simulation study. Trials. 2014;15:264. 
 36. Hammond SP, Cross JL, Shepstone L, et  al. PERFECTED enhanced recovery 
(PERFECT- ER) care versus standard acute care for patients admitted to acute settings 
with hip fracture identified as experiencing confusion: study protocol for a feasibility 
cluster randomized controlled trial. Trials. 2017;18(1):583. 
 37. Craig P, Dieppe P, Macintyre S, et  al. Developing and evaluating complex 
interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. 
 38. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: 
Medical Research Council guidance. BMJ. 2015;350:h1258. 
 39. Avery KN, Williamson PR, Gamble C, et al. Members of the internal pilot trials 
workshop supported by the hubs for trials methodology research. Informing efficient 
randomised controlled trials: Exploration of challenges in developing progression 
criteria for internal pilot studies. BMJ Open. 2017;7:e013537.
 40. No authors listed. Data Protection Act. 2018. http://www. legislation. gov. uk/ ukpga/ 
2018/ 12/ contents/ enacted (date last accessed 30 September 2019).
 41. ICH. International conference on harmonisation good clinical practice 
recommendations. https://www. ich. org/ (date last accessed 8 May 2021).
 42. Schulz KF, Altman DG, Moher D, CONSORT Group. Consort 2010 statement: 
Updated guidelines for reporting parallel group randomised trials. J Pharmacol 
Pharmacother. 2010;1(2):8):100–107:. 
 43. Hoffmann TC, Glasziou PP, Boutron I, et  al. Better reporting of interventions: 
template for intervention description and replication (TIDieR) checklist and guide. 
BMJ. 2014;348:g1687. 
 44. Baillie L, Gallini A, Corser R, Elworthy G, Scotcher A, Barrand A. Care 
transitions for frail, older people from acute hospital wards within an integrated 
healthcare system in England: a qualitative case study. Int J Integr Care. 2014;14:e009. 
Author information:
  T. Smith, PhD, Associate Professor in Physiotherapy, Senior Researcher in Rehabilita-
tion, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK; 
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, 
University of Oxford, Oxford, UK.
  L. Clark, PhD, Clinical Trial Manager
  R. Khoury, BA (Hons), Junior Trial Manager
  M- S. Man, PhD, Senior Trial Manager
  S. Hanson, PhD, Lecturer in Health Sciences
  A. Welsh, PhD, Lecturer in Physical Activity and Health
  A. Clark, PhD, Associate Professor
Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
  S. Hopewell, DPhil, Associate Professor, Nuffield Department of Orthopaedics, 
Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  K. Pfeiffer, PhD, Research Psychologist, Department of Geriatric Rehabilitation, 
Robert- Bosch- Krankenhaus GmbH, Stuttgart, Germany.
  P. Logan, Professor of Rehabilitation Research, School of Medicine, University of 
Nottingham, Nottingham, UK.
  M. Crotty, PhD, Professor of Rehabilitation, Aged & Extended Care, College of 
Medicine and Public Health, Flinders University, Adelaide, Australia; Flinders 
University, Adelaide, Australia.
  M. Costa, PhD, Professor of Orthopaedic Trauma, Nuffield Department of 
Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, 
Oxford, UK; University of Oxford, Oxford, UK.
  S. E. Lamb, DPhil, Associate Dean for Research & Mireille Gillings Professor of 
Health Innovation, College of Medicine and Health, University of Exeter, Exeter, UK; 
University of Exeter, Exeter, UK.
Funding statement:
  No benefits in any form have been received or will be received from a commercial 
party related directly or indirectly to the subject of this article. The research, includ-
ing the open access funding, is supported by the National Institute for Health Re-
search (NIHR) Research for Patient Benefit grant (NIHR200731). The views expressed 
are those of the author(s) and not necessarily those of the NHS, the NIHR or the 
Department of Health and Social Care.
ICMJE COI statement:
  M- S. Man reports a grant awarded to T. Smith from NIHR RfPB (NIHR200731) to 
conduct the study, which also partially funds Man's employment.
Data sharing:
  The data that support the findings of this study may be available from the corre-
sponding author (TS) upon reasonable request. This includes access to the full pro-
tocol, anonymized participant- level dataset, and statistical code.
Acknowledgements:
  The HIP HELPER Study Collaborators: Mrs Penny Clifford (Norfolk, PPI Representative), 
Mrs Lis Freeman (Norfolk, PPI Representative), Mr Rene Gray (Principal Investigator 
– James Paget University Hospital NHS Trust), Mrs Yan Cunningham (Principal Inves-
tigator – City Hospitals Sunderland NHS Foundation Trust), Ms Sarah Langford (Prin-
cipal Investigator – Northumbria Healthcare NHS Foundation Trust), Dr Mark Baxter 
(Principal Investigator – University Hospital Southampton NHS Foundation Trust), 
Ms Jessica Pawson – (Principal Investigator – Barts Health NHS Trust), Miss Melissa 
Taylor (James Paget University Hospital NHS Trust), Miss Anna Mellows (James Pa-
get University Hospital NHS Trust), Kate Lacey (James Paget University Hospital NHS 
Trust), Mr Alex Herring (City Hospital Sunderland NHS Foundation Trust), Diane Wil-
liams (Northumbria Healthcare NHS Foundation Trust), Anna Cromie (Northumbria 
BONE & JOINT OPEN 
T. SMITH, L. CLARK, R. KHOURY, ET AL920
Healthcare NHS Foundation Trust), Gail Menton (Northumbria Healthcare NHS Foun-
dation Trust), Warren Corbett (University Hospital Southampton NHS Foundation 
Trust), Helen Jowett (University Hospital Southampton NHS Foundation Trust), Mr 
Vishwanath Joshi (Barts Health NHS Trust), Mr Maninderpal Matharu (Barts Health 
NHS Trust).
Oversight Committee Membership: TOC Members: Associate Professor Susan Dutton 
(Chair; University of Oxford, UK), Professor Opinder Sahota (University of Notting-
ham, UK), Dr Katie Sheehan (Kings College London, UK).
Ethical review statement:
  North East - Newcastle & North Tyneside 1 Research Ethics Committee (20/NE/0213) 
35 Date: 16 March 2021.
© 2021 Author(s) et al. This is an open- access article distributed under the terms of 
the Creative Commons Attribution Non- Commercial No Derivatives (CC BY- NC- ND 4.0) 
licence, which permits the copying and redistribution of the work only, and provided 
the original author and source are credited. See https:// creativecommons. org/ licenses/ 
by- nc- nd/ 4. 0/
